HRP20040371B1 - Thiopene- amd thiazolesulfonamides as antineoplastic agents - Google Patents

Thiopene- amd thiazolesulfonamides as antineoplastic agents

Info

Publication number
HRP20040371B1
HRP20040371B1 HRP20040371AA HRP20040371A HRP20040371B1 HR P20040371 B1 HRP20040371 B1 HR P20040371B1 HR P20040371A A HRP20040371A A HR P20040371AA HR P20040371 A HRP20040371 A HR P20040371A HR P20040371 B1 HRP20040371 B1 HR P20040371B1
Authority
HR
Croatia
Prior art keywords
alkyl
halogen
thiazolesulfonamides
thiopene
amd
Prior art date
Application number
HRP20040371AA
Other languages
English (en)
Croatian (hr)
Inventor
Alfonso@De@Dios
Cora@Sue@Grossman
Philip@Arthur@Hipskind
Ho@Shen@Lin
Karen@Lynn@Lobb
Beatriz@L�pez@de@Uralde@Garmendia
Jose@Eduardo@Lopez
Mary@Margaret@Mader
Michael@Enrico@Richett
Chuan@Shih
Original Assignee
Eli@Lilly@and@Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli@Lilly@and@Company filed Critical Eli@Lilly@and@Company
Publication of HRP20040371A2 publication Critical patent/HRP20040371A2/hr
Publication of HRP20040371B1 publication Critical patent/HRP20040371B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/36—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HRP20040371AA 2001-10-25 2002-10-15 Thiopene- amd thiazolesulfonamides as antineoplastic agents HRP20040371B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35201201P 2001-10-25 2001-10-25
PCT/US2002/031568 WO2003035629A1 (en) 2001-10-25 2002-10-15 Thiopene- amd thiazolesulfonamides as antineoplastic agents

Publications (2)

Publication Number Publication Date
HRP20040371A2 HRP20040371A2 (en) 2004-08-31
HRP20040371B1 true HRP20040371B1 (en) 2012-07-31

Family

ID=23383421

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20040371AA HRP20040371B1 (en) 2001-10-25 2002-10-15 Thiopene- amd thiazolesulfonamides as antineoplastic agents

Country Status (33)

Country Link
US (2) US7084170B2 (https=)
EP (1) EP1442030B1 (https=)
JP (1) JP4464681B2 (https=)
KR (1) KR100913471B1 (https=)
CN (1) CN1298709C (https=)
AR (1) AR037248A1 (https=)
AT (1) ATE338033T1 (https=)
AU (1) AU2002334817B2 (https=)
BR (1) BR0212386A (https=)
CA (1) CA2463300C (https=)
CY (1) CY1106247T1 (https=)
DE (1) DE60214413T2 (https=)
DK (1) DK1442030T3 (https=)
EA (1) EA006081B1 (https=)
EC (1) ECSP045078A (https=)
EG (1) EG26021A (https=)
ES (1) ES2269816T3 (https=)
HR (1) HRP20040371B1 (https=)
HU (1) HUP0401638A3 (https=)
IL (2) IL160851A0 (https=)
MX (1) MXPA04003886A (https=)
MY (1) MY130718A (https=)
NO (1) NO20041316L (https=)
NZ (1) NZ531136A (https=)
PE (1) PE20030574A1 (https=)
PL (1) PL208083B1 (https=)
PT (1) PT1442030E (https=)
SI (1) SI1442030T1 (https=)
SV (1) SV2004001367A (https=)
TW (1) TWI281916B (https=)
UA (1) UA75716C2 (https=)
WO (1) WO2003035629A1 (https=)
ZA (1) ZA200403089B (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6881741B2 (en) * 2001-06-11 2005-04-19 Virochem Pharma Inc. Compounds and methods for the treatment or prevention of Flavivirus infections
SE0102616D0 (sv) * 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
US7375131B2 (en) * 2002-06-06 2008-05-20 Smithklinebeecham Corp. NF-κB inhibitors
KR101058696B1 (ko) * 2002-12-10 2011-08-22 바이로켐 파마 인코포레이티드 후라비바이러스 감염의 치료 또는 예방을 위한 화합물과방법
SE0300092D0 (sv) * 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
SE0300091D0 (sv) * 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
US20050085531A1 (en) * 2003-10-03 2005-04-21 Hodge Carl N. Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
JP5134247B2 (ja) * 2004-09-13 2013-01-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 スルホンアミド含有化合物の血管新生阻害物質との併用
WO2006030947A1 (ja) * 2004-09-13 2006-03-23 Eisai R & D Management Co., Ltd. スルホンアミド含有化合物の血管新生阻害物質との併用
US8772269B2 (en) 2004-09-13 2014-07-08 Eisai R&D Management Co., Ltd. Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
CA2599301A1 (en) * 2005-02-28 2006-08-31 Eisai R & D Management Co., Ltd. Novel use of sulfonamide compound in combination with angiogenesis inhibitor
WO2006090932A1 (ja) * 2005-02-28 2006-08-31 Eisai R & D Managemant Co., Ltd. スルホンアミド化合物の代理マーカー
SI1859793T1 (sl) 2005-02-28 2011-08-31 Eisai R&D Man Co Ltd Nova kombinirana uporaba sulfonamidne spojine za zdravljenje raka
WO2006119646A1 (en) * 2005-05-13 2006-11-16 Virochem Pharma Inc. Compounds and methods for the treatment or prevention of flavivirus infections
US7208506B2 (en) * 2005-07-07 2007-04-24 Hoffmann-La Roche Inc. Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents
US7625896B2 (en) * 2005-11-25 2009-12-01 Hoffman-La Roche Inc. Pyridylsulfonamide derivatives
US20100291592A1 (en) 2006-04-20 2010-11-18 Taro Semba Novel marker for sensitivity against sulfonamide compound
US7939532B2 (en) 2006-10-26 2011-05-10 Hoffmann-La Roche Inc. Heterocyclyl pyridyl sulfonamide derivatives, their manufacture and use as pharmaceutical agents
JP5290186B2 (ja) * 2006-11-15 2013-09-18 ヴァイロケム ファーマ インコーポレイテッド フラビウイルス感染症の治療または予防用のチオフェン類似体
JP2010526844A (ja) 2007-05-16 2010-08-05 エフ．ホフマン−ラ ロシュ アーゲー アリールピリジルスルホンアミド誘導体、それらの製造法及び医薬剤としての使用
CN101899008B (zh) * 2010-05-20 2012-10-17 中国人民解放军第二军医大学 N-取代嘧啶磺酰基-取代苯甲酰胺类化合物及其制备药物的用途
CN103450149B (zh) * 2012-06-01 2015-10-14 中国科学院上海有机化学研究所 苯基噻吩磺酰胺类化合物及其制备方法和用途
JP6364967B2 (ja) * 2014-05-30 2018-08-01 東ソー株式会社 ジチエノベンゾジチオフェンの製造方法
CN106588868A (zh) * 2016-11-16 2017-04-26 武汉理工大学 一种2‑溴‑3‑噻吩甲酸中间体的合成方法
CN108558822B (zh) * 2018-06-01 2020-12-18 盐城锦明药业有限公司 N-((5-溴噻吩-2-基)磺酰基)-2,4-二氯苯甲酰胺的合成方法
CN110835345A (zh) * 2018-08-17 2020-02-25 中国科学院上海药物研究所 一类细胞周期依赖性激酶的降解剂、其制备方法、药物组合物及其用途
CN109265437A (zh) * 2018-10-19 2019-01-25 凯莱英医药集团（天津）股份有限公司 一种3-羟基噻吩-2-羧酸酯类化合物的制备方法
WO2024251876A1 (en) * 2023-06-07 2024-12-12 KRæFTENS BEKæMPELSE PROTACs AND HyT-PD MOLECULES FOR TARGETED PROTEIN DEGRADATION OF DCAF15 AND THEIR USE IN THE TREATMENT OF AMYLOIDOSIS
WO2025031360A1 (zh) * 2023-08-09 2025-02-13 上海科技大学 磺酰胺类化合物及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0513979A1 (en) * 1991-03-26 1992-11-19 Merck & Co. Inc. Angiotensin II antagonists incorporating a substituted thiophene or furan
EP0560554A2 (en) * 1992-03-13 1993-09-15 Eli Lilly And Company Antitumor compositions and methods of treatment
US5302724A (en) * 1990-07-17 1994-04-12 Eli Lilly And Company Antitumor compositions and methods of treatment
WO1998014440A1 (en) * 1996-10-04 1998-04-09 Eli Lilly And Company Antitumor compositions and methods of treatment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA813332B (en) * 1980-06-21 1982-05-26 Pfizer Larvicides and isecticides
AU737038B2 (en) * 1996-07-05 2001-08-09 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Anti-viral pharmaceutical compositions containing saturated 1,2-dithiaheterocyclic compounds and uses thereof
JP4316787B2 (ja) 2000-01-11 2009-08-19 壽製薬株式会社 エーテル又はアミド誘導体、その製法並びにそれを含有する糖尿病治療剤、

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5302724A (en) * 1990-07-17 1994-04-12 Eli Lilly And Company Antitumor compositions and methods of treatment
EP0513979A1 (en) * 1991-03-26 1992-11-19 Merck & Co. Inc. Angiotensin II antagonists incorporating a substituted thiophene or furan
EP0560554A2 (en) * 1992-03-13 1993-09-15 Eli Lilly And Company Antitumor compositions and methods of treatment
WO1998014440A1 (en) * 1996-10-04 1998-04-09 Eli Lilly And Company Antitumor compositions and methods of treatment

Also Published As

Publication number Publication date
CA2463300A1 (en) 2003-05-01
AR037248A1 (es) 2004-11-03
NZ531136A (en) 2006-08-31
WO2003035629A1 (en) 2003-05-01
PT1442030E (pt) 2006-12-29
KR20040062583A (ko) 2004-07-07
KR100913471B1 (ko) 2009-08-25
US20060223871A1 (en) 2006-10-05
IL160851A0 (en) 2004-08-31
EG26021A (en) 2012-12-10
UA75716C2 (en) 2006-05-15
EP1442030B1 (en) 2006-08-30
HUP0401638A2 (hu) 2004-11-29
US20040198784A1 (en) 2004-10-07
CY1106247T1 (el) 2011-06-08
EA200400582A1 (ru) 2004-08-26
JP4464681B2 (ja) 2010-05-19
TWI281916B (en) 2007-06-01
JP2005511547A (ja) 2005-04-28
US7084170B2 (en) 2006-08-01
NO20041316L (no) 2004-03-30
ATE338033T1 (de) 2006-09-15
MY130718A (en) 2007-07-31
BR0212386A (pt) 2004-07-27
HK1068337A1 (en) 2005-04-29
DE60214413D1 (de) 2006-10-12
HRP20040371A2 (en) 2004-08-31
PE20030574A1 (es) 2003-07-03
ES2269816T3 (es) 2007-04-01
HUP0401638A3 (en) 2012-09-28
PL208083B1 (pl) 2011-03-31
SI1442030T1 (sl) 2006-12-31
US7250430B2 (en) 2007-07-31
ECSP045078A (es) 2004-06-28
MXPA04003886A (es) 2004-07-08
IL160851A (en) 2009-11-18
SV2004001367A (es) 2004-02-24
CA2463300C (en) 2011-07-19
ZA200403089B (en) 2005-04-22
DE60214413T2 (de) 2007-03-08
CN1575286A (zh) 2005-02-02
DK1442030T3 (da) 2006-12-27
EP1442030A1 (en) 2004-08-04
AU2002334817B2 (en) 2008-02-21
PL368234A1 (en) 2005-03-21
CN1298709C (zh) 2007-02-07
EA006081B1 (ru) 2005-08-25

Similar Documents

Publication Publication Date Title
HRP20040371B1 (en) Thiopene- amd thiazolesulfonamides as antineoplastic agents
HRP20020938B1 (en) Tropane derivatives useful in therapy
WO2003106428A8 (fr) Derives d'arylsulfonamides et leur utilisation en tant que antagonistes au recepteur b1 de la bradykinine
HRP20080226T3 (en) Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors
SE0000540D0 (sv) New compounds
CA2436846A1 (en) Thioether substituted imidazoquinolines
HRP20090162T1 (en) Quinolinone-carboxamide compounds as 5-ht4 receptor agonists
MY140572A (en) Quinazolinone derivatives as parp inhibitors
ATE431827T1 (de) Phosphonocephem-verbindung
MX9700883A (es) Derivados sustituidos de la quinazolina.
CY1107634T1 (el) Φαρμακευτικη συνθεση
HRP20110621T1 (hr) SPOJEVI PIRIDO[2,3-d]PIRIMIDINONA I NJIHOVA UPOTREBA KAO INHIBITORI PI3
ATE346067T1 (de) Carbolinderivate
MX2022015330A (es) N-fenilaminocarbonil piridino-, pirimidino y benzo-tropanos como moduladores de gpr65.
PT1181294E (pt) Novos derivados e analogos da galantamina
HRP20040230B1 (hr) Agonisti muskarina
IL150126A0 (en) Novel 4(piperazinyl(8-quinolinyl)methyl) benzamides
DE60202682D1 (de) Chinoline derivate und ihre anwendung als antitumor agentien
ATE330958T1 (de) Pyrazino 1'2':1,6öpyrido 3,4-böindolderivate
SE0101768D0 (sv) Novel compounds
HRP20080363T3 (hr) Piridin-4-il-etinil-imidazoli i pirazoli kao antagonisti mglu5 receptora
ATE293961T1 (de) Verwendung von hydantoin und seinen derivaten gegen hypalbuminämie
MXPA02011946A (es) El uso fenetilacrialamidas, fenetilacrilamidas novedosas y metodo para la produccion de las mismas.
DE69826034D1 (de) 1,2-dihydro-2-oxochinolin-derivate
YU67096A (sh) Farmaceutska jedinjenja

Legal Events

Date Code Title Description
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
A1OB Publication of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20121011

Year of fee payment: 11

PBON Lapse due to non-payment of renewal fee

Effective date: 20131015